scholarly journals CASE OF SECONDARY THROMBOTIC THROMBOCYTOPENIC PURPURA TRIGGERED BY COVID-19

2021 ◽  
Vol 19 (5) ◽  
pp. 541-545
Author(s):  
R. E. Yakubtsevich ◽  
◽  
Ye. V. Zukhovitskaya ◽  
K. M. Dorokhin ◽  
N. F. Vasilevskaya ◽  
...  

The article analyzes a clinical case of the development of thrombotic thrombocytopenic purpura (TTP) in a patient with verified COVID-19 infection. The algorithm of TTP diagnosis when ADAMTS13 biomarker test is unavailable is presented. The article presents the scheme of effective treatment of TTP with the use of plasma exchange, methylprednisolone and rituximab administration.

2020 ◽  
Vol 13 (6) ◽  
pp. e234091
Author(s):  
Sowmya Goranta ◽  
Smit S Deliwala ◽  
Tarek Haykal ◽  
Ghassan Bachuwa

Acute acquired thrombotic thrombocytopenic purpura (TTP) requires prompt recognition and initiation of plasma exchange (PEX) therapy and immunosuppression. When PEX fails, mortality nears 100%, making finding an effective treatment crucial. Primary refractory TTP occurs when initial therapies fail or if exacerbations occur during PEX therapy, both signifying the need for treatment intensification to achieve clinical remission. Rituximab helps treat most of the refractory TTP cases, except those that are severely refractory. A paucity of studies guiding severely refractory TTP makes management arbitrary and individualised, highlighting the value of isolated reports. We present an extremely rare case of primary refractory TTP with an insufficient platelet response to numerous types of treatments, including emerging therapies such as caplacizumab, on the background of repeated PEX and immunosuppressive therapies.


1999 ◽  
Vol 102 (1) ◽  
pp. 12-16 ◽  
Author(s):  
Javier de la Rubia ◽  
Aurelio López ◽  
Francisco Arriaga ◽  
Ana Rosa Cid ◽  
Ana Isabel Vicente ◽  
...  

2020 ◽  
Vol 13 (3) ◽  
pp. 1368-1372
Author(s):  
Umit Yavuz Malkan ◽  
Murat Albayrak ◽  
Hacer Berna Ozturk ◽  
Merih Reis Aras ◽  
Bugra Saglam ◽  
...  

Microangiopathic hemolytic anemia (MAHA) can be observed as a paraneoplastic syndrome (PS) in certain tumors. MAHA-related signet ring cell carcinoma (SRCC) of an unknown origin is very infrequent. Herein we present a SRCC case presented with refractory acquired thrombotic thrombocytopenic purpura (TTP). A 35-year-old man applied to the emergency service with fatigue and headache. His laboratory tests resulted as white blood cell 9,020/µL, hemoglobin 3.5 g/dL, platelet 18,000/µL. Schistocytes, micro-spherocytes, and thrombocytopenia were observed in his blood smear. MAHA was present and he was considered as having TTP. Plasma exchange treatment was initiated; however, he was refractory to this treatment. Thorax and abdomen computerized tomography revealed thickening of minor curvature in stomach corpus with hepatogastric and paraceliac lymphadenopathy. Bone marrow (BM) investigation by our clinic resulted as the metastasis of adenocarcinoma. Ulceration and necrosis were observed by gastric endoscopy procedure. Biopsy was taken during endoscopic intervention, which resulted as SRCC. MAHA may be seen as a PS in some tumors, especially gastric cancers. Tumor-related MAHA is generally accompanied by BM metastases. As a result, BM investigation may be used as the main diagnostic method to find the underlying cancer. The clinical course of cases with tumor-related MAHA is usually poor, and these cases are usually refractory to plasma exchange treatment. In conclusion, physicians should suspect a malignancy and BM involvement when faced with a case of refractory TTP.


1990 ◽  
Vol 84 (4) ◽  
pp. 209-211
Author(s):  
Yoshitoshi Itoh ◽  
Tomoyuki Taniguchi ◽  
Naoshi Takeyama ◽  
Hideki Kuriki ◽  
Takaya Tanaka

1997 ◽  
Vol 23 (1) ◽  
pp. 44-50 ◽  
Author(s):  
P. Knöbl ◽  
C. Rintelen ◽  
G. Kornek ◽  
C. Wiltschke ◽  
P. Kalhs ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document